Cargando…

Radiotherapy for extensive-stage small-cell lung cancer in the immunotherapy era

Currently, chemoimmunotherapy is the first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC). However, only 0.8%–2.5% of the patients presented complete response after chemoimmunotherapy. Considering that ES-SCLC is highly sensitive to radiotherapy, the addition of radiotherapy aft...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Huanhuan, Zhao, Yangzhi, Ma, Tiangang, Shao, Hao, Wang, Tiejun, Jin, Shunzi, Liu, Zhongshan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10493776/ https://www.ncbi.nlm.nih.gov/pubmed/37701437 http://dx.doi.org/10.3389/fimmu.2023.1132482

Ejemplares similares

Circular RNA: A potential diagnostic, prognostic, and therapeutic biomarker for human triple-negative breast cancer
por: Tian, Tian, et al.
Publicado: (2021)

Hypofractionated radiotherapy with immunochemotherapy for extensive-stage small-cell lung cancer
por: Liu, Chaoyuan, et al.
Publicado: (2023)

What is the role of consolidative thoracic radiotherapy in the era of chemo-immunotherapy for extensive stage small cell lung cancer?
por: Higgins, Kristin A., et al.
Publicado: (2020)

Is consolidative thoracic radiotherapy of extensive-stage small cell lung cancer still beneficial in the era of immunotherapy? A retrospective analysis
por: Hoffmann, Elgin, et al.
Publicado: (2023)

The role of thoracic consolidative radiotherapy in the setting of immunotherapy in extensive stage small cell lung cancer
por: Verma, Saurav, et al.
Publicado: (2023)

Immunotherapy for extensive stage small cell lung cancer
por: Pacheco, Jose M.
Publicado: (2020)

Immunotherapy in Extensive-Stage Small Cell Lung Cancer
por: El Sayed, Rola, et al.
Publicado: (2021)

Cryoablation and immunity in non-small cell lung cancer: a new era of cryo-immunotherapy
por: Velez, Antonio, et al.
Publicado: (2023)

Efficacy and safety of first-line immunotherapy plus chemotherapy in treating patients with extensive-stage small cell lung cancer: a Bayesian network meta-analysis
por: Zhang, Tianming, et al.
Publicado: (2023)

The Combination of Radiotherapy With Immunotherapy and Potential Predictive Biomarkers for Treatment of Non-Small Cell Lung Cancer Patients
por: Meng, Lu, et al.
Publicado: (2021)

The Role of Exosomes in the Female Reproductive System and Breast Cancers
por: Bai, Yuqi, et al.
Publicado: (2020)

Real-world landscape transition of death causes in the immunotherapy era for metastatic non-small cell lung cancer
por: Wu, Yijun, et al.
Publicado: (2022)

Radiotherapy improves the outcomes of immunotherapy with Sintilimab in non-small-cell lung cancer: A real-world analysis
por: Li, Shuling, et al.
Publicado: (2022)

Prospects and feasibility of synergistic therapy with radiotherapy, immunotherapy, and DNA methyltransferase inhibitors in non-small cell lung cancer
por: Jie, Chen, et al.
Publicado: (2023)

Erratum: Real-world landscape transition of death causes in the immunotherapy era for metastatic non-small cell lung cancer
Publicado: (2022)

Consolidative thoracic radiotherapy for extensive stage small cell lung cancer
por: Zhang, Xiaoli, et al.
Publicado: (2017)

Cost-effectiveness of serplulimab as first-line therapy for extensive-stage small cell lung cancer in China
por: Xiang, Guiyuan, et al.
Publicado: (2023)

Navigate Towards the Immunotherapy Era: Value of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Brain Metastases
por: Yang, Guanqun, et al.
Publicado: (2022)

Real-World Efficacy and Safety of Thoracic Radiotherapy after First-Line Chemo-Immunotherapy in Extensive-Stage Small-Cell Lung Cancer
por: Xie, Zhaoliang, et al.
Publicado: (2023)

Remarkable response to PD-1 inhibitor in a patient with extensive-stage small cell lung cancer: a case report and literature review
por: Yuan, Ge, et al.
Publicado: (2023)

One Stone, Three Birds: Multifunctional Nanodots as “Pilot Light” for Guiding Surgery, Enhanced Radiotherapy, and Brachytherapy of Tumors
por: Wang, Ze, et al.
Publicado: (2023)

Mechanistic rationales for combining immunotherapy with radiotherapy
por: Chi, Alexander, et al.
Publicado: (2023)

Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis
por: Zhu, Youwen, et al.
Publicado: (2023)

Cell Fate Reprogramming in the Era of Cancer Immunotherapy
por: Zimmermannova, Olga, et al.
Publicado: (2021)

Immunotherapy in extensive small cell lung cancer
por: Verma, Vaibhav, et al.
Publicado: (2019)

The Role of Immunotherapy in Extensive Stage Small-Cell Lung Cancer: A Review of the Literature
por: Tsiouprou, Ioanna, et al.
Publicado: (2019)

Rechallenge of immunotherapy beyond progression in patients with extensive-stage small-cell lung cancer
por: Li, Lingling, et al.
Publicado: (2022)

Immunotherapy for extensive-stage small-cell lung cancer: current landscape and future perspectives
por: Zhang, Shuang, et al.
Publicado: (2023)

Timing of thoracic radiotherapy in the treatment of extensive-stage small-cell lung cancer: important or not?
por: Luo, Jing, et al.
Publicado: (2017)

Safety and efficacy of thoracic radiotherapy combined with chemo-immunotherapy in patients with extensive-stage small cell lung cancer: a multicenter retrospective analysis
por: Cai, Zijing, et al.
Publicado: (2023)

Radiotherapy for non-small cell lung cancer in the immunotherapy era: the opportunity and challenge—a narrative review
por: Xia, Wu-Yan, et al.
Publicado: (2020)

The Effect of immunotherapy on oligometastatic non-small cell lung cancer patients by sites of metastasis
por: Ma, Jia-Chun, et al.
Publicado: (2022)

Radiotherapy: Brightness and darkness in the era of immunotherapy
por: Zhai, Danyi, et al.
Publicado: (2022)

Radiotherapy in the Era of Immunotherapy With a Focus on Non-Small-Cell Lung Cancer: Time to Revisit Ancient Dogmas?
por: Khalifa, Jonathan, et al.
Publicado: (2021)

Treatment patterns and outcomes of immunotherapy in extensive‐stage small‐cell lung cancer based on real‐world practice
por: Yang, Yaning, et al.
Publicado: (2022)

Neoantigen Targeting—Dawn of a New Era in Cancer Immunotherapy?
por: Wirth, Thomas C., et al.
Publicado: (2017)

FGFR3 Alterations in the Era of Immunotherapy for Urothelial Bladder Cancer
por: Kacew, Alec, et al.
Publicado: (2020)

Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives
por: Peyraud, Florent, et al.
Publicado: (2022)

The efficacy of adebrelimab compared with durvalumab and atezolizumab in untreated extensive-stage small-cell lung cancer: a survival analysis of reconstructed patient-level data
por: Wang, Bi-Cheng, et al.
Publicado: (2023)

Combining stereotactic body radiotherapy with immunotherapy in stage IV non-small cell lung cancer
por: Liu, Xiaoli, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_n8qgh4vgoms4hofgk2em12jjoj